Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment

Joanna M. Cain, Georgiana K. Ellis, Carolyn Collins, Benjamin E. Greer, Hisham K. Tamimi, David C. Figge, Allen M. Gown, Robert B. Livingston

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

The incidence of bone marrow involvement with epithelial ovarian cancer has been evaluated as a continuation of interest in autologous bone marrow support. Fifty-eight aspirates were obtained on 50 patients and 53 aspirates were evaluable. Immunocytochemistry with the monoclonal cytokeratin antibodies 35βH11 and 34βE12 was performed. There have been no complications. Twelve (23%) were positive and three were indeterminate. Stage, grade, and CA-125 level were not different in the two groups. No patient had a positive biopsy at the time of initial diagnosis. The majority of patients were drawn from second-look procedures; of these, 7 of 19 were positive. Five of twelve with positive aspirates died from disease versus 5 of 38 with negative aspirates, and patients with a positive aspirate had a longer overall survival time until death from disease. We can confirm the presence of epithelial ovarian cancer in 23% of patients at varying times in the course of their disease. We cannot identify risk factors for the development of this finding nor the viability of those cells when found in this data set.

Original languageEnglish (US)
Pages (from-to)442-445
Number of pages4
JournalGynecologic oncology
Volume38
Issue number3
DOIs
StatePublished - Sep 1990

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment'. Together they form a unique fingerprint.

  • Cite this

    Cain, J. M., Ellis, G. K., Collins, C., Greer, B. E., Tamimi, H. K., Figge, D. C., Gown, A. M., & Livingston, R. B. (1990). Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment. Gynecologic oncology, 38(3), 442-445. https://doi.org/10.1016/0090-8258(90)90088-3